GlassScriptPhysician profile
Hengbing Wang
NPI 1497940191
$8,670.05
in general payments reported to CMS, 2019-2025
50 companies · $2,637 in 2025
The $2,637 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $488 · 2021: $1,272 · 2022: $1,187 · 2023: $1,107 · 2024: $924 · 2025: $2,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,117 · Education: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,116.61 |
| Education | $550.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $908.26 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $835.42 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Lilly USA, LLC | $746.00 | 2019-2025 | Verzenio, Jaypirca |
| Astellas Pharma US INC | $541.27 | 2019-2025 | Xtandi, Vyloy |
| Pfizer INC. | $525.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $525.33 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $503.91 | 2019-2025 | Rybrevant, Darzalex, Carvykti |
| Glaxosmithkline, LLC. | $389.41 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $326.76 | 2019-2025 | Fruzaqla, Iclusig |
| Celgene Corporation | $295.95 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| Genentech USA, INC. | $282.05 | 2019-2025 | Tecentriq, Lunsumio, Venclexta |
| Novartis Pharmaceuticals Corporation | $281.90 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $235.96 | 2021-2025 | Ultomiris |
| Amgen INC. | $195.16 | 2019-2025 | Imdelltra (Amg757), Lumakras |
| Eisai INC. | $177.02 | 2021-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $166.66 | 2019-2023 | Tukysa |
| Daiichi Sankyo INC. | $121.73 | 2023-2025 | Enhertu, Datroway |
| Ipsen Biopharmaceuticals, INC | $120.85 | 2025 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $111.88 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Myriad Genetic Laboratories, INC. | $91.29 | 2022-2024 | Myrisk |
| Kite Pharma, INC. | $78.56 | 2021-2023 | Yescarta |
| Rigel Pharmaceuticals, INC. | $78.23 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Incyte Corporation | $77.82 | 2020-2024 | Jakafi, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $74.24 | 2023-2025 | Libtayo, Lynozyfic |
| Gilead Sciences, INC. | $73.65 | 2022-2025 | Trodelvy |
| Abbvie INC. | $68.28 | 2023-2025 | Venclexta |
| Pharmacosmos Therapeutics INC. | $57.35 | 2023-2024 | Cosela, Monoferric |
| Genzyme Corporation | $51.85 | 2020-2024 | |
| Epizyme, INC. | $50.25 | 2020-2022 | |
| Adc Therapeutics America, INC. | $46.11 | 2022-2025 | |
| Stemline Therapeutics INC. | $41.12 | 2025 | Orserdu |
| Coherus Oncology, INC. | $38.18 | 2023 | |
| Caris Mpi, INC. | $38.03 | 2025 | Mi Cancer Seek |
| Tersera Therapeutics LLC | $37.96 | 2021-2025 | Zoladex |
| Array Biopharma INC | $36.33 | 2025 | Braftovi, Mektovi, Tukysa |
| Iovance Biotherapeutics, INC. | $34.64 | 2025 | Amtagvi |
| Mirati Therapeutics, INC. | $34.44 | 2023 | Krazati |
| Acrotech Biopharma INC. | $34.16 | 2021-2025 | Beleodaq |
| Karyopharm Therapeutics INC. | $31.98 | 2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.49 | 2025 | |
| Exact Sciences Corporation | $28.03 | 2025 | Cologuard Collection Kit |
| Syndax Pharmaceuticals, INC. | $22.04 | 2025 | |
| Taiho Oncology, INC. | $21.64 | 2019 | |
| Immunomedics, INC. | $19.64 | 2020 | |
| Deciphera Pharmaceuticals INC. | $19.08 | 2025 | Romvimza, Qinlock |
| Foundation Medicine, INC. | $17.42 | 2023 | |
| Springworks Therapeutics, INC. | $16.36 | 2025 | Ogsiveo |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 | |
| Kyowa Kirin, INC. | $14.71 | 2023 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hengbing Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.